Beleave Inc. Stock

BLEVF

CA0775611084

Pharmaceuticals

Market Closed - OTC Markets 15:42:41 2026-10-29 EDT			5-day change	1st Jan Change
0.000010 ^USD	+900.00%		-.--%	+900.00%

20-06-16	Beleave Inc. Appoints Bill Panagiotakapoulos as Chief Restructuring Officer	CI
20-06-04	Hegedus Consulting Services Inc. agreed to acquire Substantially All of the Assets from Beleave Inc. (CNSX:BE).	CI

Beleave Inc. is a Canada-based cannabis company. Through its wholly owned subsidiary, Beleave Kannabis Corp, the Company is a license holder and producer of cannabis, which includes cultivation, processing, medical sales and research. Its segment includes Cannabis Products and Patient Network. Its Cannabis Products segment is a licensed producer of marihuana for medical purposes. Its Patient Network segment is a patient network of medical cannabis services. It cultivates cannabis flower, oil and extracts for medical and recreational markets. Its product line includes cannabis-infused products, oils and vape pens. The Company operates a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
BLEVF Stock

Market Cap	7.65M 6.89M 6.37M 5.76M 10.89M 717M 11.16M 76.32M 30.42M 384M 28.7M 28.09M 1.22B	P/E 2018	-4.72x	P/E 2019	-0.76x
Enterprise Value	17.96M 16.19M 14.96M 13.52M 25.58M 1.68B 26.21M 179M 71.45M 902M 67.42M 65.98M 2.87B	EV / Sales 2018	-	EV / Sales 2019	17,137,012x
Free-Float	98.39%	Yield 2018 *	-	Yield 2019	-

20-06-16	Beleave Inc. Appoints Bill Panagiotakapoulos as Chief Restructuring Officer	CI
20-06-04	Hegedus Consulting Services Inc. agreed to acquire Substantially All of the Assets from Beleave Inc. (CNSX:BE).	CI
20-04-13	Beleave Inc. Announces Management Changes	CI
20-03-02	Beleave Inc. announced that it expects to receive CAD 0.5 million in funding	CI
20-03-02	Beleave Inc. Enters LoI with Dutchman's Gold to Partner on Cannabis Infused Honey Products	CI
20-03-02	Beleave Inc. Approves for Sales in the Province of Alberta	CI
20-02-26	Beleave Expands Cannabis 2.0 Product Roll Out to British Columbia with Flyte Classic Vaporizer	CI
20-02-25	Beleave Inc. announced that it has received CAD 0.27 million in funding	CI
19-12-19	Beleave Inc. Announces New Product Line; Receives the Largest Purchase Order from A Province in the Company's History	CI
19-12-19	Beleave Inc. Announces Management Changes	CI
19-10-31	Beleave Announces Joint Venture with Volero Brands to Launch Cannabis 2.0 Products in Canada	CI
19-10-28	Beleave Inc. Announces Management Appointments	CI
19-09-18	Beleave Inc. (CNSX:BE) cancelled its acquisition of TerraFarma, Inc.	CI

20-04-29	Beleave Refiles Amended and Restated MD&A and Financial Statements	NE
20-04-20	Beleave Files Amended and Restated Financial Statements	NE
20-04-17	Beleave's Q3 Financials Should Not Be Relied Upon	NE
20-04-13	Beleave Provides Operational and Leadership Updates	NE
20-03-03	Beleave Enters LOI with Dutchman's Gold to Partner on Cannabis Infused Honey Products	NE

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0
10 years	0		0.4

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/28/20	Jeannette VanderMarel	Tax	Chief Executive Officer	2,343,750	0.4350%
4/28/20	Andrew Steane	Tax	Director	2,343,750	0.4350%
4/28/20	Kevin Keagan	Tax	Chief Executive Officer	11,718,750	2.1751%

Beleave Inc. Stock

Stocks

BLEVF

CA0775611084

Pharmaceuticals

Valuation: Beleave Inc.

Chart: Beleave Inc.

Latest news: Beleave Inc.

Press Releases: Beleave Inc.

Quotes and Performance

Price Extremes

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BELEAVE INC.	+900.00%	-.--%	-	-	5.54K
ELI LILLY AND COMPANY	+0.35%	+1.36%	+45.38%	+140.47%	1,280B
JOHNSON & JOHNSON	-0.13%	+1.48%	+44.67%	+90.43%	675B
ABBVIE INC.	+0.37%	+0.05%	+31.00%	+112.84%	521B
ROCHE HOLDING AG	+0.96%	+3.63%	+39.77%	+70.01%	386B
MERCK & CO., INC.	-0.59%	-2.11%	+61.83%	+45.16%	363B
NOVARTIS AG	+1.37%	+0.48%	+28.71%	+59.25%	301B
ASTRAZENECA PLC	+0.85%	-0.19%	+3.68%	+36.77%	286B
AMGEN INC.	+0.62%	-2.17%	+38.31%	+75.12%	253B
GILEAD SCIENCES, INC.	-0.67%	-2.72%	+38.49%	+123.56%	211B
Average	+90.65%	-0.46%	+36.87%	+83.74%	428B
Weighted average by Cap.	+0.97%	+0.20%	+39.68%	+97.40%

	2018	2019
Net sales	-	2.37 2.14 1.98 1.79 3.38 222.67 3.46 23.69 9.44 119.25 8.91 8.72 379.51
Net income	-12.64M -11.39M -10.53M -9.52M -18M -1.19B -18.45M -126M -50.28M -635M -47.45M -46.44M -2.02B	-33.78M -30.45M -28.13M -25.43M -48.11M -3.17B -49.3M -337M -134M -1.7B -127M -124M -5.4B
Net Debt	-5.2M -4.69M -4.33M -3.91M -7.41M -488M -7.59M -51.9M -20.69M -261M -19.52M -19.1M -831M	10.32M 9.3M 8.59M 7.77M 14.69M 968M 15.05M 103M 41.03M 518M 38.72M 37.89M 1.65B